Alpha Cognition wins European patent covering Zunveyl ingredient for Alzheimer’s treatment

• Alpha Cognition won a European Patent Office grant covering a crystalline form of benzgalantamine, the active ingredient in ZUNVEYL, for mild-to-moderate Alzheimer’s disease.
• Claims cover the solid form, related compositions, manufacturing methods, preparation processes, and medical-use protection.
• Patent could extend protection for benzgalantamine into 2042, subject to standard requirements.
• Grant can be validated across EPC states, supporting broader IP coverage in Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607290830BIZWIRE_USPR_____20260729_BW160832) on July 29, 2026, and is solely responsible for the information contained therein.